Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration

Allison M. Gustavson 1,*, Jennifer P. Wisdom 2, Marie E. Kenny 1, Hope A. Salameh 1, Princess E. Ackland 1,3, Barbara Clothier 1, Siamak Noorbaloochi 1,3, Adam J. Gordon 4,5,6 and Hildi J. Hagedorn 1,7

Abstract

Background: Despite the risk of negative sequelae from opioid use disorder (OUD) and clinical guidelines for the use of effective medication treatment for OUD (M-OUD), many Veterans Health Administration (VHA) providers and facilities lag in providing M-OUD. An intensive external facilitation intervention may enhance uptake in low-adopting VHA facilities by engaging stakeholders from multiple clinical settings within a facility (e.g., mental health, primary care, pain specialty clinic, substance use disorder clinics). Our study identified pre-intervention determinants of implementation through qualitative interviews, described strategies employed during the first 6 months of intensive external facilitation, and explored patterns of implementation determinants in relation to early outcomes.

Methods: Guided by the integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) framework, we interviewed stakeholders at low-adopting VHA facilities prior to external facilitation, employed a rapid qualitative analytic process, presented findings during facility visits, and collaboratively created facilitation action plans to achieve goals set by the facilities that would increase M-OUD uptake. The primary outcome was the Substance Use Disorder (SUD)-16, which is a VHA facility-level performance metric consisting of the percent of patients receiving M-OUD among those with an OUD diagnosis. We examined the relationship between pre-implementation factors and 6-month SUD-16 outcomes.

(Continued on next page)
Background

Opioid use can lead to opioid use disorder (OUD), regardless of race, sex, age, or other characteristics [1]. Veterans are at a higher risk of OUD due to increased prevalence of acute and chronic pain conditions, mental health conditions, and social stressors [2]. In 2017, more than 69,000 Veterans receiving care through the Veterans Health Administration (VHA) had a diagnosis of OUD, double from 2013 [3]. The use and misuse of prescription opioids and illicit opioids have led to an increased rate of Veterans who die from opioid overdose [4]. For those who do not die from an overdose, the negative sequelae of OUD has implications for increased healthcare utilization, [5–7] risk of human immunodeficiency virus (HIV) and hepatitis C (HCV) infection, [8] higher costs to society, [9] and poorer quality of life [10].

Medication treatment for OUD (M-OUD)—including buprenorphine, methadone, and naltrexone—is strongly recommended for OUD, should be offered to all patients with OUD, and is a covered pharmacy benefit for Veterans [11, 12]. M-OUD treatment with methadone or buprenorphine is the gold-standard treatment [11]. Methadone is a full opioid agonist that has been approved for the treatment of OUD since 1972; however, methadone can only be delivered in highly regulated Opioid Treatment Programs [13, 14]. Such programs can only accommodate a small proportion of the total number of patients with OUD who would benefit from M-OUD. Buprenorphine, introduced in the USA in 2002, is a partial opioid agonist. Numerous outpatient studies have shown that sublingual buprenorphine maintenance treatment is equally effective as moderate doses of methadone [15, 16]. In addition, buprenorphine has advantages over methadone in that it has lower abuse potential and lower risk of overdose [17, 18]. Although prescribers are required to complete 8 h of mandatory training and receive a waiver to prescribe buprenorphine, it can be prescribed in office-based settings such as primary care, mental health care, and specialty care settings in addition to Opioid Treatment Programs. Thus, buprenorphine use may provide potential for increased access to treatment through multiple entry points in the healthcare system. When M-OUD is contraindicated or not acceptable to the patient, antagonist medication (naltrexone) can be considered with the greatest promise shown with injectable naltrexone administered once per month [19, 20].

The VHA is invested in improving and increasing access to M-OUD. [12, 13] yet rates of M-OUD prescribing for the population with OUD across VHA facilities range widely from 1 to 68% [3, 21–25]. VHA’s efforts with respect to M-OUD adoption have included organization-level solutions, which tend to consist of passive diffusion (e.g., through guideline development) [11]. Generally, such strategies are successful in only some locations which can lead to improvements in overall national quality indicators; however, such strategies can leave groups of low-adopting facilities—and consequently their patient populations—behind. Variability in M-OUD adoption suggests that active, targeted implementation
strategies such as intensive external facilitation (e.g., coaching, mentoring) are required to promote change in clinical practice. External facilitation is a multi-faceted process by which external implementation experts work with facility stakeholders to promote interactive problem-solving and knowledge exchange that supports the adoption of evidence-based practice in the context of the targeted facility [26, 27].

We sought to determine whether employing a 12-month intensive external facilitation intervention enhances implementation of M-OUD at low-adopting VHA facilities [28]. This study focused primarily on implementation of buprenorphine due to the lower regulatory burden of prescribing buprenorphine compared to methadone and the higher level of evidence for effectiveness compared to naltrexone. The project will also encourage implementation of injectable naltrexone for cases where buprenorphine is not a viable or acceptable alternative for a particular patient. The Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD) study engaged stakeholders across multiple clinic setting within the facility (e.g., primary care, mental health, pain specialty clinic, substance use disorder specialty clinic) and included an on-site visit with the research team, active goal setting, education, M-OUD training, and monthly facilitation calls [28]. The study is based on the integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) framework, which hypothesizes that implementation success of a clinical innovation is driven by active facilitation with recipients (e.g., providers, leaders, patients) in their context (e.g., clinical setting) [29]. Prior to employing the external facilitation intervention, we conducted pre-implementation, qualitative interviews with stakeholders and then rapidly analyzed the data to inform facilitation action plans (i.e., site-specific steps and goals to increase M-OUD). Facilitation began with a site visit where the facilitators and individuals at the local facilities worked together to develop an action plan that could be executed rapidly to address barriers and leverage facilitators. Following the site visit, facilitators worked collaboratively with each site on their goals over the course of 1 year [28]. The purpose of this mixed methods study is to (1) categorize pre-implementation barriers and facilitators through use of qualitative inquiry with key stakeholders at intervention facilities, (2) describe the strategies employed during the first 6 months of intensive external facilitation, and (3) explore patterns of barriers and facilitators identified pre-implementation in the context of 6-month quantitative outcomes.

Methods
Mixed methods overview
The 12-month Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD) intervention is described elsewhere [28]. Briefly, for this mixed methods study, we conducted a qualitative, developmental formative evaluation of providers and leadership at low-adopting VHA facilities using semi-structured interviews prior to the intensive external facilitation intervention to identify barriers and facilitators to implementation of M-OUD. We analyzed interviews using a rapid qualitative review process [30], presented the preliminary results to the providers and leaders at each site during the site visit, and subsequently used the results to formulate an action plan with goals and corresponding strategies to achieve goals. Finally, we assessed 6-month outcomes in the context of ongoing facilitation efforts to assess for early response to the intervention. We used the Standards for Reporting Implementation Studies (StaRI) checklist to report our implementation study [31].

Sample
As previously described, [28] we initially selected 35 VHA facilities in the bottom quartile based on the facility proportion of OUD patients with an OUD diagnosis receiving M-OUD, reported as a percent. The goal was to have eight facilities randomly selected and invited to voluntarily participate in the intensive external facilitation intervention. If a facility declined to participate, then they were replaced by another randomly selected site. Of the 14 facilities approached, eight agreed to participate and six declined. All remaining facilities with low M-OUD adoption served as controls (N=27). Only intervention facilities were interviewed for qualitative data. The purpose of this manuscript is to describe the identified barriers and facilitators in relation to 6-month quantitative outcomes in intervention facilities, and therefore, we do not present quantitative data from control facilities here. Participants interviewed included leadership and clinical staff from primary care, mental health, pain specialty care, and substance use disorder (SUD) clinics.

Data collection and analysis
First, to assess local conditions at each site the research team conducted developmental formative evaluations through interviews with stakeholders to identify barriers and facilitators to implementing M-OUD. The i-PARIHS framework guided the qualitative interviews and identified determinants of implementation success or hindrance within the innovation, recipient, and context constructs [29]. i-PARIHS defines innovation as the intervention characteristics, including the complexity of the intervention, relative advantage compared to current practice or another intervention, usability, and evidence to support the intervention, including research-based evidence, clinical experience, and patient preferences. For this study, the innovation is M-OUD [29]. Context includes aspects internal to the organizational setting,
such as leadership support, culture, organizational priorities, evaluation and feedback processes, and learning networks, as well as issues outside the organization, such as policy drivers and priorities, incentives and mandates, and inter-organizational networks [29]. Recipients includes characteristics of the people who enact and influence the implementation, such as their motivation, values and beliefs, goals, skills and knowledge, time, resources and support, local opinion leaders, collaboration and teamwork, and power and authority [29].

Research team members (HJH, HVM, MEK, PEA, HAS) conducted individual phone interviews with consented leadership and providers at each site. The first participants approached for interview were the SUD clinic directors and program coordinators, who then identified other key leaders and clinical stakeholders to approach for a voluntary interview. Stakeholders included psychiatrists, pharmacists, clinicians, and nurses across multiple clinical service lines including primary care, mental health, and pain specialty clinics. Stakeholders were not necessarily included from all clinics (primary care, mental health, pain) at every facility as interviews were targeted to those in clinics that were deemed most essential and most interested in participating in the effort. Phone interviews were recorded and transcribed, followed by a rapid analysis of data to inform the site-specific action plans (goals and strategies to achieve goals) and external facilitation intervention for each site. To rapidly analyze the data, research team members (HJH, HVM, MEK, PEA, HAS) individually read all transcribed interviews from a site and garnered a comprehensive list of barriers and facilitators. The team met to verify barriers and facilitators identified at each site and created a final site summary detailing the barriers and strengths as well as potential strategies that facilities could employ to increase M-OUD. The research team repeated this process for all intervention facilities. For a later, more comprehensive qualitative analysis, two researchers (HAS, MEK) individually categorized barriers and facilitators identified in the site summaries into the primary i-PARIHS constructs: context, innovation, or recipients. The two researchers then met to resolve conflicts with a third researcher (HJH) providing consultation as needed.

Next, the external facilitators (HJH and AJG) presented the site summaries during the in-person site visits to each clinical team (voluntary providers and leaders at each site). The collective review of the site reports allowed the clinical team to check the major identified barriers and identify any key barriers missed. Additionally, input from the clinical team was designed to promote greater feasibility of the action plan and effectiveness of selected implementation strategies. Details on the external facilitation intervention are described elsewhere [28]. Briefly, site visits were scheduled over 1–2 days depending on the educational needs of the site. Consistent components of facilitation included at all site visits were review of the site report as a group, education for the clinical team on M-OUD topic areas and available resources, and engagement of the clinical team in identifying goals and strategies to achieve goals. Site visits were staggered over a 15-month period, beginning in March of 2018 and ending June of 2019. Site visits were followed by 12 months of facilitation, including monthly coaching calls, ending in July of 2020. All facilities had completed a minimum of 6 months of the intervention prior to the COVID pandemic. Researchers (HJH and MEK) reviewed progress notes gathered from the first 6 months of telephone meetings with the facilities to assess whether goals were achieved. If the site indicated the goal was accomplished by the 6-month call, the goal was considered accomplished ("Yes"). If significant progress had been made toward the goal, it was indicated as "In progress." If no progress or very little progress had been made, the goal was not considered accomplished ("No").

Finally, we investigated the relationship between barriers and facilitators with the primary outcome of the SUD-16 metric, which is a VHA metric defined by clinical operations that indicates the percent of patients with an OUD diagnosis receiving M-OUD treatment (formulations of methadone, buprenorphine, naltrexone). These patients with OUD are served by the facility and its associated community-based clinics in the past year. The SUD-16 metric is reported quarterly for each fiscal year. The SUD-16 for the fiscal year and quarter just prior to the facility visit date and any prior interviews was used as baseline data. The SUD-16 for the fiscal year and quarter ending about 6 months after the on-site facility visit was used for 6-month data (last site December 31, 2019). We analyzed the facility change in SUD-16 from baseline to 6 months using independent two sample z-tests, since we did not have patient level data to assess the extent of dependency between the two periods. We reported 95% confidence intervals. Statistical significance was determined at $p<0.05$. Because the true correlation between baseline and 6 months is unknown, but assumed positive, the above test yields larger standard errors and hence larger $p$ values implying the reported $p$ values are conservative.

Results

We interviewed 68 out of the 85 stakeholders approached for participation, resulting in an 80% completion rate (3 refusals and 14 unable to schedule interviews before facility visit). Table 1 summarizes VHA facility characteristics and the roles of interviewed stakeholders ($N=68$, range 7–11 per facility). Each facility had at least three interview participants each in the leadership and clinical provider categories. The facilities represented...
diverse geographical locations with two out of the 8 facilities classified as geographically located in rural areas [18]. While six of eight facilities were categorized as “urban,” only one of these was in a major metropolitan area.

Study Question 1: What are barriers and facilitators identified by VHA facilities?

Table 2 describes examples of barriers and facilitators within selected, pre-defined i-PARIHS categories of innovation, context, and recipients. It is possible for a construct to be both a barrier and a facilitator, even within the same facility. The innovation construct’s sub-element “degree of fit with existing practice and values” is one example. Many clinicians endorsed the need to manage patients stabilized on buprenorphine in their clinic (facilitator), yet they often had trouble identifying which patients with OUD on their panels might be appropriate to manage outside of a substance use disorder specialty care setting (barrier). We chose to illustrate a few key barriers and facilitators that were common across all VHA facilities and frequently integrated into many of the facility-specific action plans [22−24]. Innovation barriers and facilitators included degree of fit with existing practice and values, clarity, and relative advantage. In terms of degree of fit, some clinicians mentioned processes already in place regarding where and when to treat patients with M-OUD that would help facilitate increased prescribing and management of patients with M-OUD. Meanwhile, at other facilities, the current processes for approving an M-OUD prescription were extensive and thus clinicians cited this as a barrier to M-OUD implementation. Overall, clinicians at many facilities perceived a lack of clarity in policies and processes regarding who treats patients with M-OUD outside of the specialty SUD clinics. To match the high demand for M-OUD in Veterans, clinician and leadership stakeholders perceived the relative advantage of providing M-OUD throughout the VHA over existing practices limiting the provision of these services to within SUD specialty care clinics.

Context barriers and facilitators were spread across local, organizational, and external health system levels. Overall, stakeholders described more facilitators than barriers at the local level with the most frequently mentioned being local level mechanisms for embedding change, meaning stakeholders reported positive perceptions of the facility’s past experience with employing processes to enact practice change. At the organizational level, stakeholders perceived that facility-level leadership was promoting a strong call to action to prioritize improvement of SUD-16 metrics but may have been inundated by the multiple VHA initiatives concurrently in place. At the external health system level, environmental stability was affected by the rurality of some facilities which subsequently impacted leadership’s ability to recruit and maintain trained and waivered providers.

Recipient-related barriers and facilitators included motivation, skills, knowledge, time, resources, and support. Stakeholders perceived that providers at low-adopting VHA facilities wanted to complete the required training to apply for the United States Drug Enforcement Administration (DEA) waiver necessary to prescribe buprenorphine but also indicated not all providers had a shared interest depending on the provider’s team or clinic. For example, primary care providers often expressed concerns with large caseloads and limited resources as a reason for not expanding access to buprenorphine to their clinics. Citing skills and knowledge as a determinant of buprenorphine implementation depended on whether the facility already employed a provider who possessed a DEA waiver and had experience prescribing buprenorphine. Adequate space and provider capacity (number of providers, caseload per provider, and number of additional staff) were perceived as important barriers or facilitators to implementation of buprenorphine (Table 2).
Table 2: Examples of barriers and facilitators described by facilities and classified by i-PARIHS constructs

| i-PARIHS construct | Barrier example | Facilitator example |
|--------------------|-----------------|---------------------|
| **Innovation** (focus or content of innovation effort) | Degree of fit with existing practice and values | Approval for buprenorphine is difficult given current requirements for 4 positive consecutive urine drug screens for opiates and no other substances | An established pain clinic has a current role in identifying patients with OUD, initiating buprenorphine, and transferring care back to primary care |
| | Clarity | M-OUD treatment is referred to community clinics (non-VHA providers), so roles and responsibilities of VHA staff regarding M-OUD is not clear | Facility currently has clear criteria that patient misuse or diversion (selling) of buprenorphine results in loss of medication eligibility |
| **Context** (multiple layers that can facilitate or constrain implementation) | Local level: Mechanisms for embedding change | Clinic staff attempted to remove restrictions on where buprenorphine initiations could occur (currently only in the emergency room in a separate building); however, they were met with resistance due to concerns for adverse events related to buprenorphine initiation | Facility previously identified team to clarify and implement buprenorphine initiation strategies to increase access |
| | Organizational level: Organizational priorities | VHA employs multiple initiatives to improve Veteran care, which often leads to competing priorities | Organizational leadership is aware SUD-16 metric is low and are requesting improvement |
| | External Health System Level: Environmental stability | Rurality of facility brings the challenge of maintaining an adequate number of trained and waivered staff to provide adequate coverage | No facilitators reported |
| **Recipients** (people who enact and influence the implementation) | Motivation | Limited interest from non-SUD disciplines and clinics to manage patients on buprenorphine | Providers want to get the necessary training to prescribe buprenorphine |
| | Skills and knowledge | Facility does not have a provider who is waivered to prescribe | Facility has a new provider with experience in a buprenorphine clinic |
| | Time, resources, and support | Lack of adequate space and provider capacity to prescribe buprenorphine and manage an increase in patient caseload | Mental health residential programs have staff who can be re-allocated to provide buprenorphine and manage patients |

Study Question 2: What strategies were employed as part of the intensive external facilitation intervention?

Table 3 describes the facility-selected goals and strategies employed as part of the intensive external facilitation strategy during the initial 6 months following the on-site, facility visit. Facilities identified a range of 3–5 goals. Goals were related to expanding capacity of clinics to prescribe, implementing buprenorphine prescribing across different clinics (i.e., residential mental health, outpatient mental health, primary care, SUD clinics, and pain clinics), increasing access through different mechanisms of care delivery (e.g., telehealth), or by transferring care after initiation to other providers (e.g., primary care, mental health) for maintenance. For each goal, facilities and external facilitators worked together to establish 1–4 strategies to accomplish the identified goal. Strategies included identifying education topics, increasing the number of DEA waivered prescribers through provision of required training and facilitation of the waiver application process, identifying teams or providers available to deliver care management to patients on buprenorphine, determining criteria for monitoring of patients on buprenorphine, investigating incentive options for providers to increase buprenorphine prescribing, and revising protocols regarding where buprenorphine initiations can take place and which providers should be involved. Facilities had varying degrees of success in achieving their goals, ranging from zero to almost all goals achieved in the first 6 months (Table 3).
| Facility | Goals | Strategies identified | Achievement of goals |
|----------|-------|-----------------------|----------------------|
| Facility 1 | Implement buprenorphine prescribing in outpatient mental health clinic | 1. Identify temporary care management staffing prior to new nurse hire <br>2. Ensure prescribing privileges for all relevant outpatient mental health prescribers <br>3. Create scheduling mechanisms for outpatient mental health providers to treat patients with buprenorphine | Yes |
| | Implement buprenorphine prescribing in pain clinic | 1. Provide waiver training and privileging for prescribers <br>2. Pharmacy to assist with care coordination to reduce burden on providers | In progress |
| | Implement buprenorphine prescribing in residential mental health program | 1. Create templates in the electronic medical record to facilitate accurate documentation of buprenorphine visits <br>2. Provide waiver training and privileging for prescribers | Yes |
| | Educate primary care providers on buprenorphine | 1. Schedule seminar or cyber seminar with national subject matter expert <br>2. Develop and present medical grand rounds with local subject matter expert | Yes |
| Facility 2 | Conduct pilot to transfer one patient on buprenorphine to another waivered provider outside of SUD for maintenance monitoring | 1. Determine criteria providers would accept for stable patients on buprenorphine to transfer back into their care (e.g., number of consecutive clean urine screens) | No |
| | Examine M-OUD policies to maximize patient eligibility and ensure safety needs are addressed | 1. Provider to review other VHA policies, revise current policy, and send to subject-matter expert for review | No |
| | Identify incentives to encourage providers to obtain waivers and treat patients with buprenorphine | 1. Investigate incentive options for potential prescribers | In progress |
| | Implement pharmacy care management model for patients on buprenorphine in primary care | 1. Identify pharmacy lead <br>2. Assess willingness of waivered primary care provider to prescribe buprenorphine and hand-off management to pharmacy | In progress |
| Facility 3 | Develop outpatient buprenorphine clinic in mental health clinic | 1. Determine whether provider can have a half day clinic in the main mental health clinic | Yes |
| | Provide buprenorphine initiations in pain clinic that was soon to be established | 1. Form a team of providers focused on treating pain who are willing and have capacity to provide buprenorphine initiations | No |
| | Identify primary care and mental health providers who are willing to have stable patients on buprenorphine returned to them from community providers to prescribe in house | 1. Identify providers who are willing and have the capacity to manage patients on buprenorphine in caseload | Yes |
| | Implement buprenorphine prescribing in VHA satellite clinic | 1. Identify actionable steps for making progress in prescribing buprenorphine in a VHA satellite clinic | No |
| Facility 4 | Implement buprenorphine prescribing in a VHA substance abuse treatment program | 1. Provider to complete waiver training to prescribe <br>2. Renew community contracts for one more year to allow new prescriber to bring patients on M-OUD back to VHA gradually | Yes |
| | Develop mechanism to transfer stable patients on buprenorphine from VHA substance abuse treatment program back to VHA mental health or primary care providers | 1. Identify mental health and primary care providers that are waivered and willing to oversee management of patients on buprenorphine already on their caseload. <br>2. Identify mental health and primary care providers who are waivered and willing to take patients on buprenorphine who are not already on their caseload. | No |
Table 3 Implementation strategies within the external facilitation intervention used to address barriers or leverage facilitators to M-OUD at low-adopting VHA facilities (Continued)

| Facility | Goals | Strategies identified | Achievement of goals |
|----------|-------|-----------------------|----------------------|
| **Facility 5** | Implement buprenorphine prescribing in primary care through a team focused on pain | 3. Identify additional training or resources that these providers would need to feel comfortable managing patients on buprenorphine | |
| | | 1. Identify resources to prescribe buprenorphine | Yes |
| | Implement incentives for providers to become credentialed and prescribe | 1. Request financial incentives from mental health regional leadership | Yes |
| | Expand buprenorphine prescribing in mental health | 1. Increase number of waivered, credentialled prescribers in clinic | No |
| | Expand buprenorphine prescribing to a pain clinic | 1. Increase number of waivered, credentialled prescribers in clinic | Yes |
| | Identify options for transferring stable patients back to primary care | 1. Determine criteria providers would accept for transfer of stable patients on buprenorphine back into their care (e.g., number of consecutive negative urine screens) | No |
| | Provide initiatives in the Mental Health residential program | 1. Identify education and observation opportunities for clinic staff to increase comfort with initiations | No |
| **Facility 6** | Implement buprenorphine prescribing in pain clinic | 1. Hire an addiction specialist to increase capacity to prescribe | No |
| | Implement buprenorphine prescribing in mental health same day access clinic | 1. Determine pharmacy processes for buprenorphine dispensing for same day access | In progress |
| | | 2. Evaluate implementation of warm hand offs from mental health same day access clinic to general mental health clinic one month after initiation for patients on buprenorphine | |
| | | 3. Identify nurse champion who can follow up with patients weekly while in access clinic to support other providers and nurses during buprenorphine stabilization phase | |
| | | 4. Identify provider available as interim coverage for patient education on buprenorphine side-effects, obtain consent for treatment, register patients in the state prescription drug monitoring program, and provide naloxone kits | |
| | Implement buprenorphine in care teams focused on homeless Veterans | 1. Increase number of waivered prescribers in clinic | No |
| | Increase access to buprenorphine maintenance through telehealth | 1. Utilize waivered prescriber to administer telehealth for stable mental health patients on buprenorphine who live far from clinic | No |
| | Minimize local restrictions on buprenorphine prescription access | 1. Remove requirement for providers to receive pharmacy approval prior to prescribing buprenorphine | No |
| **Facility 7** | Implement buprenorphine prescribing in pain clinic | 1. Hire a part-time psychiatrist or an addiction fellow in the pain clinic to prescribe buprenorphine for patients with pain and OUD | In progress |
| | | 2. Obtain approval from pharmacy to allow physicians with a waiver in the pain clinic to prescribe buprenorphine for patients with pain and OUD | |
| | Implement buprenorphine prescribing in behavioral health and outpatient substance abuse clinic | 1. Increase buprenorphine prescribing by currently waivered providers in both clinics | Yes |
| | | 2. Increase number of waivered providers in behavioral health clinic to increase capacity to prescribe | |
| | Implement M-OUD prescribing in community-based outpatient clinics | 1. Consult with nursing leadership about nurses assisting telehealth mental health providers in community-based outpatient clinics | In progress |
Table 3 Implementation strategies within the external facilitation intervention used to address barriers or leverage facilitators to M-OUD at low-adopting VHA facilities (Continued)

| Facility | Goals | Strategies identified | Achievement of goals |
|----------|-------|-----------------------|----------------------|
| Facility 8 | Expand locations for initiation of buprenorphine by removing local restrictions | 1. Meet with nursing leadership to discuss removing local restrictions that initiations must occur in the emergency room 2. Revise standard operating procedure to remove local restrictions on where initiations can occur 3. Meet with pharmacy to discuss mailing buprenorphine to allow clinics without pharmacies to initiate buprenorphine | Yes |
| | Streamline process for approval for initiation for faster patient access to buprenorphine | 1. Determine which steps are essential in the current process of reviewing patients during a weekly committee meeting and which can be removed to expedite access to treatment | Yes |
| | Implement buprenorphine prescribing in residential substance use treatment program | 1. Reach consensus on strategy to time buprenorphine initiation either prior to admission to the residential program or at discharge from the residential program | Yes |
| | Increase number of prescribers in primary care | 1. Identify incentives to encourage providers to obtain waivers and treat patients with buprenorphine 2. Develop nurse care management model with nursing leadership. 3. Establish criteria for patients on buprenorphine to return to primary care provider for maintenance | No |

Study Question 3: How did the pattern of the pre-implementation facilitators/barriers impact early 6-month outcomes?

Table 4 displays the quantitative data with the SUD-16 at baseline and 6 months post facility visit and the difference (6-month baseline). Baseline SUD-16 percent proportions ranged from 4.0% to 34.9%. Seven out of eight facilities improved on their SUD-16 at a range of 4.3 to 9.9%, with two facilities demonstrating statistically significant increases (facilities 4 & 5). Facility 6 had the largest baseline SUD-16 at 34.9% and was the only facility to experience a negative difference (−3.6%), though not statistically significant (Table 4).

The supplementary material provides a visual representation of the mixed methods results representing the patterns of pre-intervention barriers and facilitators in the context of the quantitative SUD-16 change from baseline to 6 months. Under innovation, the extent to which buprenorphine prescribing aligned with existing clinical practices and values (i.e., degree of fit) was present as a barrier, facilitator, or both at all facilities prior to the intervention, with little pattern noted in respect to the SUD-16 change. The lack of clarity in roles and procedures around buprenorphine prescribing was noted as a barrier in the facilities with the greatest change in SUD-16. Under recipients, the only construct that showed a pattern consistent with quantitative outcomes was skills & knowledge (i.e., possessing the information and ability to implement buprenorphine) with four of the lowest performing facilities identifying it as a barrier and two of the highest performing facilities identifying it as a facilitator. Under context, barriers at the
wider healthcare and regulatory policy level (i.e., external health system) were present in the six facilities with lowest rank-order change in SUD-16. The two facilities with the least change in SUD-16 indicated a higher number of facilitators at the local VHA-facility level compared to the other six facilities.

Discussion
The results of this study achieved our purpose by identifying pre-intervention barriers and facilitators to implementation of M-OUD in low-adopting VHA facilities, illustrating the strategies used during the external facilitation intervention to achieve facility-specific goals, and generating hypotheses regarding the pattern of barriers and facilitators in the context of 6-month quantitative outcomes.

First, the nature of the pre-intervention barriers found in this study were similar to other studies exploring factors impeding VHA-wide uptake of M-OUD including scarce availability of prescribers, limited staff training, inadequate space, patient and provider interest, or lack thereof [22–24, 27]. Our study found that facility goals focused on reducing barriers rather than leveraging the positive impact of facilitators. However, facilities may choose to address specific barriers that are conducive to concurrently leveraging a facility’s facilitators. For example, a facility may select a goal to implement M-OUD in mental health (to address a gap) by leveraging the collaborative teamwork already in place. Future research is needed to explore the interaction between barriers and facilitators to optimize facilitation strategies and tailor to specific facility needs.

Second, the results of the facility-specific facilitation action plan at 6 months were variable with facilities ranging from achieving or progressing towards most goals to facilities that did not achieve or demonstrate progress towards goals. These varying results indicate some barriers (e.g., staff shortages, credentialing restrictions) may be too complex to overcome by facilitation alone over the course of 6 months. Thus, acknowledging and discussing modifiable versus non-modifiable barriers as part of the external facilitation plan is critical to working collaboratively with facilities to develop informed and feasible goals. Additionally, integration of buprenorphine within other clinics that have not traditionally prescribed it (e.g., primary care, mental health, pain specialty clinic) may not be achieved early in implementation; however, the external facilitation likely lays the groundwork and subsequent momentum to expand buprenorphine prescribing to other clinics outside of substance use disorder specialty clinics. The removal of “silos” through multi-level integration of care is important for implementation of buprenorphine since patients can potentially be identified for appropriate treatment and managed across multiple disciplines (e.g., mental health, primary care, pain specialty clinics, community-based services) [21]. Future efforts are needed to address broader issues such as insufficient workforce capacity, variation in state policies regarding M-OUD, and paucity of clinical guidelines for transferring patient care across disciplines and clinics.

Third, the mixed methods results regarding the determinants of M-OUD implementation in the context of the external facilitation intervention and 6-month quantitative outcomes generate more hypotheses regarding the patterns of barriers and facilitators that may promote or hinder the adoption of buprenorphine. For innovation, the degree of fit with existing practice and values was perceived as an important construct to address with the external facilitation to improve adoption. Understanding current processes and how changes in the present conditions to increase buprenorphine adoption may be more or less disruptive to the local environment can inform the external facilitation intervention and, ultimately, drive outcomes.

### Table 4

| Facility  | SUD-16 at baseline (%) | SUD-16 at 6 months post facility visit (%) | Difference in SUD-16 (6-month baseline) (%) | 95% CI |
|----------|------------------------|-------------------------------------------|-------------------------------------------|--------|
| Facility 6 | 34.9                   | 31.3                                      | −3.6                                      | (−9.5 to 2.2%) |
| Facility 1 | 4.0                    | 7.4                                       | 3.4                                       | (−4.4 to 12.4%) |
| Facility 7 | 18.8                   | 23.1                                      | 4.3                                       | (−0.7 to 9.3%) |
| Facility 3 | 10.4                   | 17.3                                      | 6.9                                       | (−0.7 to 14.5%) |
| Facility 8 | 28.5                   | 35.6                                      | 7.1                                       | (−0.4 to 14.5%) |
| Facility 2 | 15.6                   | 23.3                                      | 7.7                                       | (−2.7 to 18.2%) |
| Facility 4 | 4.1                    | 12.5                                      | 8.4                                       | (4.4 to 12.4%) |
| Facility 5 | 19.2                   | 29.1                                      | 9.9                                       | (3.6 to 16.2%) |

*aQuarterly SUD-16 measures
*Without patient level data, independent percent proportions are assumed at each time point
‡Statistically significant at p < 0.05
For context, the salient pattern was the presence and number of barriers in the constructs related to the wider healthcare system and regulatory policies (i.e., external health system). As such, facilities with barriers at the external health system level may demonstrate limited capacity to respond to the external facilitation because overcoming these may be a prerequisite to improving adoption of buprenorphine at the local level. A second noted pattern was rather counterintuitive, showing the two facilities with the least change in SUD-16 perceived a higher number of facilitators at the local level compared to the other six facilities. Drawing upon the discussion in Hagedorn & Heideman’s work implementing hepatitis services in SUD treatment, [32] perhaps stakeholders at facilities with more perceived contextual facilitators prior to the external intervention became quickly frustrated when experiencing setbacks during the initial efforts to increase M-OUD prescribing [32–35]. Whereas facilities with a defensive pessimistic view set low expectations for performance and anticipated setbacks, thereby taking action to prepare for or manage barriers to increasing use of M-OUD [32–35].

For recipients, barriers related to skills and knowledge and values and beliefs appeared addressable through external facilitation, as reflected in the strategies and goal achievement in the facility-specific action plans. Most stakeholders perceived motivation as a facilitator, which suggests willingness to engage in M-OUD adoption. However, despite the presence of motivation, these facilities were considered low-adopting per the baseline SUD-16 measure and thus needed a more active approach to implementation of M-OUD, hence the external facilitation intervention. Interestingly, only a few facilities indicated collaboration and teamwork was either a facilitator and barrier; however, all facilities focused at least one goal on implementing buprenorphine in a clinic or with a provider team that had not previously prescribed buprenorphine or taken on the management of patients on buprenorphine (e.g., primary care, mental health). Perhaps, the issue of collaboration and teamwork was unmasked during the facility visit with external facilitators (after the provider interviews) as cross-clinic teams worked together to strategize ways of increasing adoption of buprenorphine. A logical step identified for several facilities was to expand the number of DEA-waivered prescribers across disciplines (e.g., mental health, primary care) and increase inter-clinic provider capability and capacity to manage patients on buprenorphine. Thus, during the facility visit and subsequent 6 months of external facilitation, facilities may have encountered barriers or facilitators to teamwork and collaboration that they had not considered prior to the facility visit.

This study is unique in that we used rapid qualitative analysis of pre-implementation interviews with stakeholders regarding determinants of M-OUD implementation to inform and quickly tailor the external facilitation intervention to fit facility-level needs. Academic detailing is an effective educational outreach strategy commonly used to impact care in this patient population by targeting uptake of evidence-based practice at the provider level [30, 36]. Academic detailing [30, 36] and other approaches [21, 37] designed to promote uptake of evidence-based practice could benefit from this rapid, developmental approach to tailoring implementation strategies to fit the complex and dynamic interaction between the clinical innovation (M-OUD), recipients, and context. Our mixed methods analysis of 6-month outcomes helps us to understand whether implementation interventions and strategies can make meaningful change in facility metrics quickly to, ultimately, impact patient outcomes. This study has several limitations. First, the study was conducted in VHA facilities, all of which volunteered to participate after initial selection, which limits the generalizability; however, perhaps because these facilities were considered low-adopting facilities per their SUD-16 measure (lowest quartile in the SUD-16 measure among all VHA facilities), many were eager to participate. Like other facility metrics, SUD-16 is a facility performance metric where facility and regional leaders receive compensation based on facility performance. Second, interview participants volunteered to participate, and thus, the information gathered may be biased compared to a sample of providers who were randomly selected to provide qualitative data. To address this, we carefully crafted the interview guide to include questions and probes that sought to understand the facility’s culture and perspectives regarding M-OUD, not just the interviewee’s perspective alone. General sampling rather than a random sample for qualitative inquiry targets key stakeholders to ensure the perspectives of those involved in and/or impacted by the implementation effort are gained [38]. Third, qualitative data was collected at one time-point, prior to the external facilitation, and may not capture barriers or facilitators that occurred during the first 6 months of external facilitation intervention, such as staff turnover. We are collecting qualitative data after the full year of external facilitation, which—juxtaposed on the pre-intervention data—will likely capture changes in patterns of facilitators and barriers that may impact study results.

The full effect of the intensive external facilitation on change in M-OUD prescribing at low-adopting VHA facilities will be observed at the completion of the parent ADApT-OUD study (12 months following facility visits) [28]. Early results from our study can assist other implementation efforts to increase adoption of M-OUD in the
VHA by identifying patterns of barriers and facilitators more or less conducive to change in uptake of M-OUD [21]. Future research will explore patterns of barriers or facilitators and the facilitation response over the course of the 12-month external facilitation intervention to determine how the types, sequence, and timing of implementation strategies impacted M-OUD adoption at the various facilities.

Conclusions
Our study addresses the variability in delivery of M-OUD across the VHA and is aligned with current VHA and non-VHA initiatives to address the opioid crisis. Over the initial 6 months of the study, intensive external facilitation to promote accomplishment of facility goals demonstrated a signal for positively impacting M-OUD prescribing in almost all low-adopting VHA facilities. The signal in our mixed methods analysis of 6-month outcomes indicates change at the facility level can occur during the initial external facilitation intervention phase. Changes in facility metrics allow stakeholders to experience short-term wins that may strengthen the long-term sustainability of M-OUD prescribing. Accelerating the implementation of M-OUD at low-adopting VHA facilities is time-sensitive given the increasing prevalence of OUD and the negative societal and individual implications associated with OUD. Enhancing adoption and sustainability of M-OUD is critical to optimizing positive outcomes for Veterans and non-Veterans with OUD across the nation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s43058-021-00119-8.

Additional file 1: Table 1. Patterns of barriers and facilitators coded within the i-PARIHS framework from facility summaries, ranked by the magnitude of within-facility difference in SUD-16.

Abbreviations
ADaPT-OUD: Advancing Pharmaceutical Treatments for Opioid Use Disorder; DEA: Drug Enforcement Agency; i-PARIHS: integrated-Promoting Action on Research Implementation in Health Services framework; M-OUD: Medication for opioid use disorder; OUD: Opioid use disorder; SUD: Substance use disorder; SUD-16: VHA performance metric of the percent of patients receiving M-OUD out of all patients with OUD diagnosis; VHA: Veterans Health Administration

Acknowledgments
We acknowledge and thank Dr. Helen Valenstein-Mah, PhD, LP, for her tremendous work completing provider interviews and participating in the rapid qualitative analysis. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

Authors’ contributions
HIH conceptualized the study. AJG and HIH obtained funding. HIH, AJG, PEA, BC, SN, and MEK designed the study. HIH, AJG, PEA, MEK, and HAS implemented the study. BC and SN analyzed the quantitative data. HIH, PEA, MEK, HAS, AMG, and JPW analyzed the qualitative data. HIH, PEA, MEK, HAS, AMG, JPW, AJG, BC, and SN interpreted the mixed method analysis. AMG wrote the initial draft with all other authors providing feedback and revisions. The authors read and approved the final manuscript.

Funding
This study was funded by the Veteran Administrations Health Services Research and Development Investigator Initiated Research Project #16-14S; Minneapolis Center of Innovation, Center for Care Delivery and Outcomes Research (CIN 13-406); and the Veterans Health Administration Office of Academic Affiliations Advanced Fellowship in Clinical and Health Services Research (TPH 67-000). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

Availability of data and materials
De-identified data can be obtained by contacting the corresponding author.

Ethics approval and consent to participate
Ethical approval was obtained from the Veterans Affairs Institutional Review Board (#16-23).

Consent for publication
Authors consent for publication of this article.

Competing interests
The authors declare they have no competing interests.

Author details
1Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Health Care System, 1 Veterans Drive, Mail Code #152, Minneapolis, MN 55417, USA. 2Wisdom Consulting, New York, NY 10010, USA. 3Department of Medicine, University of Minnesota, Minneapolis, USA. 4Vulnerable Veteran Innovative PACT (VIP) Initiative; Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS), VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148, USA. 5Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Salt Lake City, Utah, USA. 6Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 7Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.

Received: 1 May 2020 Accepted: 28 January 2021
Published online: 15 February 2021

References
1. Burdess SG, Gordon AJ. A crisis of opioids and the limits of prescription control. United States. Addiction. 2019;114(1):169–80.
2. Shiner B, Leonard Westgate C, Bernardy NC, Schnurr PP, Watts BV. Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. J Dual Diagnosis. 2017;13(3):201–12.
3. Wyse JJ, Gordon AJ, Dobsha SK, Monaco BJ, Tiffany E, Drexl K, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139–44.
4. Lin LA, Peltzman T, McCarthy JF, Oliva EM, Trafton JA, Bohnert AS. Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. Am J Prev Med. 2015;57(1):106–10.
5. Kison NY, Shei A, Rice JB, Elbke CJ, Bodnar K, Birbaum HG, et al. The burden of undiagnosed opioid abuse among commercially insured individuals. Pain Med. 2015;16(7):1325–32.
6. Rice JLB, Kison NY, Shei A, Cummings AK, Bodnar K, Birbaum HG, et al. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy. 2014;12(4):435–46.
7. Roland CL, Joshua AV, Mardian J, Walden SC, Harnett J. Prevalence and cost of diagnosed opioid abuse in a privately insured population in the United States. J Opioid Manag. 2013;9(3):161–75.
8. Perlman DC, Jordan AE. The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions. Curr HIV/AIDS Rep. 2018;15(2):96–112.
9. Bimbau HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657–67.
10. Hagmaier NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Ann J Managed Care. 2018;24(10 Suppl):S290–S6.
11. Management of Substance Use Disorders. U.S. Department of veteran affairs. https://www.healthquality.va.gov/guidelines/mh/sud/. Published 2015. Accessed 27 January 2021.
12. Mental Health Residential Rehabilitation Treatment Program Washington, DC. Department of Veterans Affairs, Veterans Health Administration; 2019. https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=8400. Accessed 27January 2021.
13. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiates use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515–32.
14. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. https://doi.org/10.1002/14651858.CD002209.pub2.
15. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.
16. Ling W, Chavuvassta C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–86.
17. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch General Psychiatry. 1997;54(8):713–20.
18. Strain EC, Sitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151(7):1–25.
19. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37.
20. Krupitsky E, Nunes EV, Ling W, Ilieperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377(9766):1506–13.
21. Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275–82.
22. Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidissaty S, Aghvami M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychiatr Addict Behav. 2011;25(2):215–24.
23. Oliva EM, Harris AH, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend. 2012;122(3):241–6.
24. Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(3):374.
25. Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Substance abuse. 2018;39(3):286–8.
26. Implementation facilitation training manual: Department of Veterans Affairs, Veterans Health Administration Version 3, 2020. https://www.queriesearch.va.gov/tools/implementation/Facilitation-Manual.pdf. Accessed 27 January 2021.
27. Hagedorn HJ, Brown R, Davies M, Diepenink E, Myrick DH, Oliva EM, et al. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci. 2015;11(131):9–37.
28. Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noobaloochi S, Yu W, et al. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract. 2018;13(1):25.
29. Harvey G, Kitson A. PARBS revisited: from heuristic to integrated framework for the successful implementation of knowledge into practice. Implement Sci. 2016;11:33.
30. Gale RC, Wu J, Erhardt T, Bounthavong M, Reardon CM, Damschroder LJ, et al. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019;14(1):11.
31. Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for reporting implementation studies (StaRI) statement. BMJ. 2017;356:i6795.
32. Hagedorn HJ, Heldeman PW. The relationship between baseline Organizational Readiness to Change Assessment subscale scores and implementation of hepatitis prevention services in substance use disorders treatment clinics: a case study. Implement Sci. 2010;5(1):46.
33. Norem JK, Cantor N. Defensive pessimism: harnessing anxiety as motivation. J Personality Soc Psychol. 1986;55(4):1208.
34. Norem JK, Chang EC. The positive psychology of negative thinking. J Clin Psychol. 2002;58(9):993–1001.
35. Weiner BJ, Amick H, Lee S-YD. Conceptualization and measurement of organizational readiness for change: a review of the literature in health services research and other fields. Med Care Res Rev. 2008;65(4):379–436.
36. Midboe AM, Wu J, Erhardt T, Carmichael JM, Bouthavong M, Christopher MLD, et al. Academic detailing to improve opioid safety: lessons from a qualitative evaluation. Pain Med. 2018;19(suppl_1):S46–53.
37. Rogal SS, Chinman M, Gellad WF, Mor MK, Zhang H, McCarthy SA, et al. Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. Implement Sci. 2020;15(1):148.
38. Hamilton AB, Finley EP. Qualitative methods in implementation research: an introduction. Psychiatry Res. 2019;288:112516.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

*At BMC, research is always in progress.*

Learn more [biomedcentral.com/submissions](http://biomedcentral.com/submissions)